ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

Rhea-AI Summary

ImmuCell (Nasdaq: ICCC) appointed Kathy Turner to its Board of Directors effective April 1, 2026, replacing retiring director Steven Rosgen. Turner will chair the Compensation and Stock Option Committee and join the Audit Committee.

She brings 30+ years of global commercial leadership across animal health and healthcare, including prior board service at Elanco and senior roles at IDEXX and Abbott, and will support expansion of the First Defense® product internationally.

Positive

• Board addition adds 30+ years of global animal health and commercial leadership
• Committee roles Chair of Compensation and Stock Option Committee; member of Audit Committee
• International growth experience from IDEXX and Abbott could support First Defense® expansion

Negative

• Board turnover departure of a long-tenured director after 8 years may reduce continuity

News Market Reaction – ICCC

+1.82%

+1.82% Session close to close

In the Mar 19 session, ICCC gained 1.82%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018. Upon joining the Board, Ms. Turner will serve as Chair of the Compensation and Stock Option Committee and as a member of the Audit Committee.

Ms. Turner brings more than three decades of commercial executive leadership experience in global healthcare and animal health markets and previously served on the Board of Directors of Elanco Animal Health, a leading animal health company. From 2014 to 2023, she held senior leadership roles at IDEXX Laboratories, including most recently serving as Chief Marketing Officer and Senior Vice President of International Operations, where she contributed to sustained double-digit growth across international markets. Prior to that, Ms. Turner spent nearly 30 years at Abbott Laboratories, where she held multiple leadership roles in global commercial operations. She currently serves on the Board of Veterinarians Without Borders.

Olivier te Boekhorst, President and Chief Executive Officer of ImmuCell, commented, “Kathy brings deep experience across the global animal health industry, including her service on the Board of Elanco Animal Health and her leadership in scaling international businesses at IDEXX and Abbott. Her perspective will strengthen our Board as we pursue opportunities to extend the reach of First Defense^® in the U.S. and internationally.”

Ms. Turner said, “I am excited to join the Board of ImmuCell. Its hyperimmune colostrum technology and First Defense^® product line are a compelling platform with meaningful opportunities for growth, and I look forward to supporting the team as it works to expand the reach of its calf health innovations across global animal health markets.”

The Company sincerely thanks Mr. Rosgen for his many valuable contributions during 8 years of dedicated service.

About ImmuCell:

ImmuCell Corporation (Nasdaq: ICCC) is an animal health biologics company serving the dairy and beef industries with practical, science-based solutions that improve the survivability, health, and long-term performance of dairy and beef calves. The Company’s primary product line, First Defense^®, provides Immediate Immunity™ through orally delivered antibodies against the principal viral and bacterial causes of scours, one of the most prevalent and deadly diseases in neonatal calves worldwide. Press releases and other information about the Company are available at http://www.immucell.com.

Contacts:	Olivier te Boekhorst, President and CEO Timothy C. Fiori, Chief Financial Officer ImmuCell Corporation investor.relations@immucell.com
	Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC iccc@lythampartners.com

FAQ

When will Kathy Turner join the ImmuCell (ICCC) board and whom does she replace?

Kathy Turner joins the ImmuCell board effective April 1, 2026, replacing Steven Rosgen. According to ImmuCell, Rosgen is retiring after serving on the board since January 2018, and Turner will assume committee responsibilities upon joining.

What committee roles will Kathy Turner hold on the ImmuCell (ICCC) board?

Upon joining, Turner will chair the Compensation and Stock Option Committee and serve on the Audit Committee. According to ImmuCell, these assignments align with her executive experience and governance background in animal health and healthcare.

How does Kathy Turner’s background support ImmuCell’s First Defense® expansion plans?

Turner brings senior commercial experience and international scaling expertise from IDEXX and Abbott. According to ImmuCell, her background and Elanco board service are expected to help extend First Defense® reach in U.S. and global markets.

Why did ImmuCell appoint Kathy Turner to the board (ICCC)?

ImmuCell appointed Turner to strengthen board expertise in global animal health and commercial growth. According to ImmuCell, her leadership is intended to support opportunities to expand First Defense® domestically and internationally.

Who is retiring from ImmuCell’s board and how long did they serve before Kathy Turner’s appointment?

Steven Rosgen is retiring from ImmuCell’s board after serving since January 2018. According to ImmuCell, Rosgen contributed eight years of service prior to Turner’s appointment effective April 1, 2026.